CUTANA™ Genomic Services
Gene Regulation Insights for Modern Drug Discovery
EpiCypher’s CUTANA™ Genomic Services provide a direct view into gene regulation, the “software” of the genome that determines how genetic information drives cell-type– and disease-specific gene expression programs. Because changes in gene activity ultimately drive drug response, gene regulatory insights are essential for understanding mechanism of action across diverse therapeutic strategies.
Our industry-validated CUTANA™ workflows deliver reproducible, genome-wide data that reveal how your compound influences this regulatory software in cells. With expert-led CUT&RUN, DNA Methylation, and Fiber-seq Services, we link molecular intervention to downstream regulatory effects, enabling clearer interpretation of target biology, earlier detection of resistance, and more confident decision-making throughout drug discovery.
Deliver high-quality genomic data that strengthen MoA hypotheses, inform biomarker strategy, and accelerate programs from discovery through development.
As our partner, you can expect:
- Detailed, end-to-end experimental design
- Expert optimization for targets, cell types, tissues, and clinical samples
- Reliable profiling using automated assays and standardized controls
- A comprehensive data report and presentation by our scientists
- Scalable protocols from pilot tests to high-throughput studies
Have a Project in Mind?
We’re here to help. Tell us more about your experiment, and our Expert Services team would be thrilled to help you get started!
CUTANA™ Genomic Services
Featured Customers
Easy Onboarding - Expert Guidance - Timely Completion
Selected Publications
- Agustinus et al. Epigenetic dysregulation from chromosomal transit in micronuclei. Nature 619, 176-183 (2023). PMID: 37286593.
- Baysoy et al. The interweaved signatures of common-gamma-chain cytokines across immunologic lineages. Journal of Experimental Medicine 220 (2023). PMID: 36976164.
- Asberry et al. Reprogramming landscape highlighted by dynamic transcriptomes in therapy-induced neuroendocrine differentiation. Computational and Structural Biotechnology Journal 20, 5873-5885 (2022). PMID: 36382181.